摘要
目的观察口服马来酸氟吡汀联合美洛昔康在急性腰扭伤的临床疗效及安全性。方法选取四川省人民医院2017年3月～2018年3月收治的急性腰扭伤患者60例为研究对象,按照随机数字表法分为观察组和对照组,每组30例。对照组患者仅给予口服美洛昔康7.5mg,qd;观察组患者给予口服马来酸氟吡汀0.1g,tid,美洛昔康7.5mg,qd。两组均治疗168h。观察并比较两组治疗后第24、48、72、96、120、144、168h时的视觉模拟评分(VAS)及功能障碍指数(ODI)。记录两组不良反应发生情况。结果观察组治疗后第48、72、96、120、144、168h时的VAS值比对照组组明显降低(P<0.05),ODI分值与对照组比较,亦明显降低(P<0.05)。两组组间比较无差异;两组治疗第24h的VAS、ODI评分比较,差异无统计学意义(P>0.05),且两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论马来酸氟吡汀联合美洛昔康具有良好的镇痛效果,可用于急性腰扭伤的治疗,且不良反应发生较少。
Objective To observe the clinical efficacy and safety of flupirtine combined with meloxicam in the treatment of acute lumbar sprain. Methods 60 patients of acute lumbar sprain by Sichuan People's Hospital in March 2017 to March 2018 were divided into observation Group (Group F, 30 cases) and the control group (Group M, 30 cases), according to the Random digital table method. Patients in Group M were given administration of meloxicam 7.5mg, qd. Group F was treated with flupirtine 0.1g tid combined with meloxicam 7.5mg qd. Both groups were treated for 168h. Visual analogue scoring (VAS) and dysfunction index (ODI) were observed at 24, 48, 72, 96, 120 144 and 168h after admission. The occurrence of adverse reactions in two groups was recorded. Results The VAS values at 48, 72, 96, 120, 144 and 168h in Group F were significantly lower than those in Group M (P<0.05). The ODI scores at 48, 72, 96, 120, 144 and 168h in Group F were significantly lower than those in Group M (P<0.05). There was no difference between the two groups. There was no significant difference in the VAS and ODI scores between the two groups in the first 24h(P>0.05). There was no significant difference in the incidence of adverse drug reactions between group F and group M (P>0.05). Conclusion The combination of flupirtine and meloxicam has good analgesic effect and can be used for the treatment of acute lumbar sprain, with fewer adverse reactions.
作者
林涛
江平
宋俊梅
LIN Tao;JIANG Ping;SONG Junmei(Department of Anesthesiology , Sichuan Provincial People's Hospital, Chengdu 610072, China;Cardiac Function Division , Sichuan Provincial People f s Hospital, Chengdu 610072, China)
出处
《西部医学》
2019年第4期548-550,556,共4页
Medical Journal of West China
基金
四川省卫生和计划生育委员会科研课题(16PJ460)
